Biochemistry Department, Hospital Sant Joan de Déu, Barcelona, Spain.
Adv Exp Med Biol. 2009;652:117-28. doi: 10.1007/978-90-481-2813-6_8.
Coenzyme Q (CoQ) is an essential component of the respiratory chain but also participates in other mitochondrial functions such as regulation of the transition pore and uncoupling proteins. Furthermore, this compound is a specific substrate for enzymes of the fatty acids beta-oxidation pathway and pyrimidine nucleotide biosynthesis. Furthermore, CoQ is an antioxidant that acts in all cellular membranes and lipoproteins. A complex of at least ten nuclear (COQ) genes encoded proteins synthesizes CoQ but its regulation is unknown. Since 1989, a growing number of patients with multisystemic mitochondrial disorders and neuromuscular disorders showing deficiencies of CoQ have been identified. CoQ deficiency caused by mutation(s) in any of the COQ genes is designated primary deficiency. Other patients have displayed other genetic defects independent on the CoQ biosynthesis pathway, and are considered to have secondary deficiencies. This review updates the clinical and molecular aspects of both types of CoQ deficiencies and proposes new approaches to understanding their molecular bases.
辅酶 Q(CoQ)是呼吸链的必需组成部分,但也参与其他线粒体功能,如调节过渡孔和解偶联蛋白。此外,这种化合物是脂肪酸β-氧化途径和嘧啶核苷酸生物合成中酶的特定底物。此外,CoQ 是一种抗氧化剂,作用于所有细胞膜和脂蛋白。至少十种核(COQ)基因编码的蛋白质合成 CoQ,但它的调节是未知的。自 1989 年以来,越来越多的患有多系统线粒体疾病和神经肌肉疾病的患者被发现 CoQ 缺乏。由任何 COQ 基因突变引起的 CoQ 缺乏被指定为原发性缺乏。其他患者表现出与 CoQ 生物合成途径无关的其他遗传缺陷,被认为是继发性缺乏。这篇综述更新了这两种类型的 CoQ 缺乏的临床和分子方面,并提出了理解其分子基础的新方法。